1. INTRODUCTION {#sec1}
===============

Abdominal aortic aneurysm (AAA) is a common disease that causes segmental dilatation and rupture of the aorta. AAA has a high mortality rate, especially in older men \[[@r1], [@r2]\]. Patients with large AAAs that are at high risk of rupture are treated by surgical repair. However, when surgical treatment is not an option, an AAA inevitably progresses, increasing in diameter and consequently increasing the rupture risk. Notably, close observation alone is recommended for patients with small AAAs; there are no alternatives to surgical repair that are available for these patients. There have been considerable efforts focused on developing medical treatments, especially pharmacotherapy, for AAA \[[@r3]-[@r7]\]. AAA is characterized by chronic inflammation and by the degradation of the extracellular matrix (ECM) by proteolytic enzymes, such as matrix metalloproteinases (MMPs);  together, these lead to segmental dilatation of the aortic wall and eventually to rupture \[[@r7]-[@r10]\]. Although the real cause of AAA onset remains unknown, AAA progression is thought to be driven by factors that include hemodynamic stress and smoking. These multifactorial causes accelerate the immune and inflammatory responses in AAA tissue. Various inflammatory mediators, such as cytokines, chemokines, and prostaglandins, as well as the renin-angiotensin system, are involved in maintaining and augmenting the inflammatory responses, including inflammatory cell infiltration. Intracellular signaling molecules, such as c-Jun N-terminal kinase (JNK) and nuclear factor-κB (NF-κB), are activated by most inflammatory mediators, while activated signaling pathways enhance the expression of inflammatory mediators, thus propagating a vicious cycle of chronic inflammation. In turn, inflammatory signaling pathways activate ECM degradation enzymes, such as MMP-9, and lead to vascular smooth muscle cell (VSMC) dysfunction, thereby causing an overall loss of elastic fibers and AAA progression (Fig. **[1](#F1){ref-type="fig"}**). These mechanisms are supported by accumulating evidence that the progression of AAA in animal models can be suppressed by pharmacologic intervention that target various aspects of these pathophysiological processes.

2. CURRENT STATUS {#sec2}
=================

2.1. Basic Studies of Pharmacologic Therapy for AAA {#sec2.1}
---------------------------------------------------

### 2.1.1. Studies Using Animal Models of AAA Progression {#sec2.1.1}

Although researchers have identified a large number of potential targets for the treatment of AAA, a limited number of them have been investigated using *in vivo* animal models of AAA progression. Golledge *et al.* noted that many rodent studies assess the effect of interventions in limiting AAA development rather than the effect of the agent on pre-established AAA \[[@r5]\]. Importantly, current animal models of AAA, including the elastase model, calcium chloride model, xenograft model, and angiotensin II model, have two disease phases: first, the initial development phase, which is model-specific; second, the progression phase, which mostly recapitulates human disease \[[@r11], [@r12]\]. An intervention that is used throughout the entire experimental period cannot distinguish between effects on the progression phase *versus* effects on the initial development phase. This review focuses on studies that have demonstrated that the pharmacologic intervention inhibits the progression phase of preexisting AAA in animal models (Table **[1](#T1){ref-type="table"}**). In these studies, interventions were started after the initial development of AAA, and the primary outcome was a change in AAA growth that was assessed by measuring the maximal aortic diameter.

Most of the interventions shown in Table **[1](#T1){ref-type="table"}** target immune/inflammatory responses among several aspects during AAA progression. Specifically, these interventions demonstrated that regulating proinflammatory mediators, including cytokines \[[@r13]-[@r15]\], the renin-angiotensin system \[[@r16], [@r17]\], and prostaglandin metabolism \[[@r18], [@r19]\], was effective in slowing the progression of preexisting AAA. Treatment with immunosuppressive agents \[[@r20], [@r21]\] and interventions that inhibit inflammatory signaling pathways \[[@r22]-[@r24]\] were also shown to be effective in stopping AAA progression. Indeed, our group reported previously that treatment with the JNK-specific inhibitor SP600125 after AAA formation reduced the diameter of the aneurysm and restored the once-disrupted elastic lamellae \[[@r22]\]. Our recent study also demonstrated that phase-limited inhibition of focal adhesion kinase (FAK) could block further progression of pre-existing AAA in a mouse model \[[@r25]\]. In addition, interventions that abrogate ECM degradation using MMP inhibitors \[[@r26], [@r27]\] or pentagalloyl glucose (PGG) \[[@r28], [@r29]\] are effective in preventing AAA progression. Recently, the pharmacological inhibition of necroptosis was reported to stabilize preexisting AAA \[[@r30]\].

### 2.1.2. Studies Using Human AAA Explant Cultures {#sec2.1.2}

Although animal studies have been important for demonstrating proof-of-concept and for assessing the efficacy and safety of new pharmacologic therapies, there are considerable differences in the pathophysiology of humans *versus* animal models. Accordingly, experiments that use *ex vivo* cultures of human AAA tissue are conducted in addition to animal studies \[[@r22], [@r36], [@r37]\]. The major advantage of *ex vivo* cultures is that one can apply therapeutic agents directly to human tissue, bypassing concerns about systemic effects or safety. However, there is always the question of whether an agent will have a similar effect *in vivo*. Thus, *in vivo* animal models and *ex vivo* cultures of human tissue are complementary approaches. Although the widespread use of endovascular aneurysm repair (EVAR) is making it more difficult to utilize human AAA tissues, both types of studies are valuable and contribute to our understanding of AAA. Table **[2](#T2){ref-type="table"}** summarizes the studies that have investigated pharmacologic therapy in human AAA explant cultures. These studies mainly assessed the secretion or the production levels of marker proteins, such as MMPs, interleukins, and monocyte chemotactic proteins (MCPs), rather than using the AAA growth rate as in *in vivo* studies.

Most of the interventions shown in Table **[2](#T2){ref-type="table"}** targeted the immune/inflammatory responses during AAA progression, except for one study that showed the effectiveness of an MMP inhibitor \[[@r36]\]. Interventions that regulate proinflammatory mediators, including cytokines \[[@r38]\], the renin-angiotensin system \[[@r39], [@r40]\], and prostaglandin metabolism \[[@r41]-[@r44]\], reduced the levels of AAA-related markers. Interventions that inhibit inflammatory signaling pathways were also effective in human AAA tissues \[[@r22], [@r25], [@r45]\]. In addition, our group demonstrated that 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) inhibit the Rac1/NF-κB pathway, thereby suppressing MMP-9 and chemokine secretion in human AAA walls \[[@r46]\].

2.2. Clinical Studies of Pharmacologic Therapy for AAA {#sec2.2}
------------------------------------------------------

### 2.2.1. Previous and Ongoing Clinical Trials {#sec2.2.1}

Clinical trials are critical for developing new ways to treat diseases. A single randomized clinical trial or multiple large non-randomized studies are needed to provide unambiguous evidence to support the safety and efficacy of pharmacologic therapy for AAA. A large cohort study and a systematic review of clinical trials for AAA treatment were conducted previously \[[@r51], [@r52]\]. In this article, we focus on randomized clinical trials of pharmacologic interventions for AAA (Tables **3** and **4**). All of these randomized clinical trials aimed to evaluate the efficacy of a pharmacologic therapy in limiting the progression of small AAA. Therefore, growth rate was commonly used as the primary outcome, and the maximal AAA diameter was measured using ultrasonography (US). Computed tomography (CT) and magnetic resonance imaging (MRI) is currently being used to assess the AAA diameter in ongoing trials. Indeed, AAA diameter remains the most widely used and the most important marker of disease progression, because large diameter and a rapid increase in the AAA diameter are thought to be risk factors for rupture and are generally accepted as an indication for surgical repair \[[@r53]\]. Notably, there is large individual variability in growth patterns. The sample sizes in previous trials varied, but current (ongoing) trials are larger, with more than 100 patients, and they have follow-up periods greater than one year.

*Chlamydia pneumoniae* is suspected to play a pathogenic role in AAA development, although this has not been proven. Accordingly, several randomized clinical trials have been conducted to test the efficacy of antibiotic treatment. Mosorin *et al.* first published a randomized trial of doxycycline, a tetracycline antibiotic, in patients with small AAAs. They showed that the expansion rate of AAAs treated with doxycycline was slower than with placebo, but the difference did not reach statistical significance \[[@r54]\]. Treatment with roxithromycin, a macrolide antibiotic, significantly reduced the AAA expansion rate \[[@r55], [@r56]\]. However, it is not clear whether the effect was due to its anti-microbial or anti-inflammatory activities. Later, a randomized clinical trial of azithromycin, another macrolide antibiotic, was conducted in a larger population, but found no effect on the AAA growth rate \[[@r57]\]. More recently, the effect of doxycycline, which was tested as an MMP inhibitor, was examined in a randomized clinical trial in a larger number of patients. That trial found that doxycycline treatment did not reduce AAA growth \[[@r58]\]. Propranolol, a β-blocker, was one of the first drugs to successfully inhibit the development of experimental AAAs in animal models \[[@r59], [@r60]\], and this prompted researchers to conduct clinical studies to test its effect on the growth of small AAAs. However, in a randomized trial, patients with AAAs did not tolerate propranolol well, and the drug did not significantly affect the growth rate of small AAAs \[[@r61]\]. Also recently, two randomized trials of pemirolast \[[@r62]\], a mast cell inhibitor, and perindopril \[[@r63]\], an angiotensin-converting enzyme (ACE) inhibitor, were conducted, but the results were disappointing (Table **[3](#T3){ref-type="table"}**).

There are currently several ongoing randomized clinical trials that aim to assess the effects of the following on the growth rate of small AAAs: doxycycline (NCT01756833), an MMP inhibitor; ticagrelor (NCT02070653), a platelet aggregation inhibitor; telmisartan (NCT01683084)/valsartan (NCT01904981), an angiotensin II receptor blocker (ARB); cyclosporine A (NCT02225756), an immunosuppressive agent; and eplerenone (NCT02345590), an aldosterone antagonist (Table **[4](#T4){ref-type="table"}**). Interestingly, several clinical studies have demonstrated an association between statin administration and decreased AAA growth \[[@r64]-[@r67]\]. However, the beneficial effect of statins has not been confirmed in larger non-randomized clinical trials \[[@r68], [@r69]\]; notably, a randomized clinical trial of statins may not be feasible, because statins are already prescribed to many patients with AAA \[[@r70]\].

### 2.2.2. Recommendation in Clinical Practice Guidelines {#sec2.2.2}

Several practice guidelines strongly recommend that patients with a fusiform AAA measuring 5.5 cm or larger undergo repair in the absence of significant co-morbidities and that most patients with a fusiform AAA measuring 5.4 cm or smaller should be monitored. These guidelines include the American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines \[[@r71]\], the Society for Vascular Surgery (SVS) Guidelines \[[@r72]\], the AAA Guidelines of the European Society for Vascular Surgery (ESVS) \[[@r2]\], and the European Society of Cardiology (ESC) Guidelines \[[@r73]\]. Notably, all strongly recommend smoking cessation to slow AAA growth. However, there is no strong recommendation regarding pharmacotherapy to reduce the risk of AAA progression and rupture. At the present time, there is only a very weak recommendation that the use of statins and ACE inhibitors be considered to reduce the risk of AAA growth \[[@r72], [@r73]\]. Table **[5](#T5){ref-type="table"}** summarizes recommendations for the medical management of AAA in the current practice guidelines.

3. FUTURE PERSPECTIVE {#sec3}
=====================

3.1. Pharmacologic Therapy for Primary Prevention {#sec3.1}
-------------------------------------------------

Because AAA is life-threatening, preventing AAA rupture is an important goal. We are hopeful that in the future, pharmacologic treatment will play a key role in the primary, secondary, and tertiary prevention of AAA (Table **[6](#T6){ref-type="table"}**). In primary prevention, the goal of pharmacotherapy is to reduce the incidence of AAA, but there is not yet a clear way to do this due to a lack of understanding of the mechanisms underlying AAA. Although it is widely accepted that multifactorial causes, including smoking and hypertension, drive the progression of AAA (Fig. **[1](#F1){ref-type="fig"}**), the primary cause of AAA onset remains unclear. If the cause is identified, a drug or drugs can be identified or developed and utilized to prevent the onset of AAA. Therefore, researchers should continue to investigate the pathogenesis underlying AAA.

There are several known risk factors that contribute to AAA development, such as hypertension and hypercholesterolemia \[[@r72]\]. The incidence of AAA might be reduced by appropriate pharmacologic treatment of these risk factors. Avoiding the risk factors and increasing physical activity to reduce the risk factors might also reduce the incidence of AAA. Moreover, the pharmacologic management of cardiovascular risk factors is generally important in people at high risk of developing AAA \[[@r2]\].

3.2. Pharmacologic Therapy for Secondary Prevention {#sec3.2}
---------------------------------------------------

The goal of pharmacotherapy for the secondary prevention of AAA is to reduce disease progression and the risk of surgical referral. Many patients presenting with AAAs measuring less than 5.5 cm are simply monitored, while treatments such as surveillance or early repair remain controversial in the management of patients with AAAs between 4.0 cm and 5.4 cm in diameter \[[@r72], [@r73]\]. Therefore, pharmacologic therapy to prevent AAA progression, or ideally to reverse AAA formation, would have a huge impact on the management of patients with small AAA once it is established and becomes a first-line treatment, replacing surveillance and early repair.

Unfortunately, no pharmacotherapy for AAA has been realized despite great effort, and there are several challenges that need to be addressed (Table **[7](#T7){ref-type="table"}**). First, it is possible that appropriate drug targets in human AAA have not been identified. Indeed, many animal studies have assessed the effects of interventions in limiting AAA development rather than the effects on pre-established AAA. In addition, the experimental opportunities for analyzing human AAA specimens have decreased in recent years. To gain a better understanding of human AAA pathophysiology and pathogenesis, continued efforts are essential, including the appropriate use and interpretation of animal models and full utilization of human samples. Second, it is important for pharmacotherapy to be sufficiently concentrated at the AAA site, but few pharmacokinetic approaches have been tested. Golledge *et al.* suggested that inappropriate dosage may underlie the negative findings in previous clinical trials \[[@r5]\]. Since AAA is predominately localized to a limited site on the aorta, it is reasonable to strive for local delivery of therapeutic agents in order to increase therapeutic efficacy and reduce systemic side effects. The efficacy of local administration was previously reported using doxycycline in rodent models of AAA \[[@r74], [@r75]\]. Notably, Nosoudi *et al.* recently reported the effects of AAA-targeted delivery of drugs using nanoparticles \[[@r27], [@r29]\], which seems to represent an attractive strategy for inhibiting AAA progression. Third, there is a possibility that the heterogeneity of human AAA might not be fully appreciated or taken into account when testing therapeutic agents, since patients with AAA are heterogeneous in terms of their characteristics, clinical history, and genetic background \[[@r10], [@r76]\]. In addition, human AAA tissue itself is spatiotemporally heterogeneous in terms of histopathological characteristics \[[@r7]\]. Therefore, it may be better to stratify AAA patients according to the predominant biological activities; towards this end, we must identify biomarkers that accurately reflect biological activity in AAA. If we can optimize therapeutic regimens for individual patients using biomarkers (personalized medicine), we may be able to achieve more effective outcomes with pharmacologic therapy and prevent or slow AAA progression.

3.3. Pharmacologic Therapy for Tertiary Prevention {#sec3.3}
--------------------------------------------------

In tertiary prevention, the goal of pharmacotherapy is to reduce AAA-related complications and mortality in patients with AAAs measuring 5.5 cm or larger. In the absence of significant co-morbidities, these patients should undergo surgical repair. Accordingly, pharmacotherapy for tertiary prevention is expected to serve as an adjuvant treatment to reduce peri- and postoperative complications as well as to improve the results of EVAR. The ESVS guidelines \[[@r2]\] already recommend that statins be started one month prior to surgical intervention to reduce cardiovascular morbidity, since statin therapy improves perioperative and postoperative outcomes after AAA repair \[[@r77]-[@r79]\]. β-blockers are also recommended for patients with ischemic heart disease, and these can be started one month before the intervention \[[@r2], [@r71]\]. Because AAA patients often have several comorbidities that significantly affect the outcome of AAA repair, pre-operative care strategies, especially pharmacotherapy, may help improve post-intervention morbidity and mortality.

Notably, ongoing aortic wall degeneration and the subsequent failure of aneurysm exclusion, such as endoleaks, is a major concern after EVAR. To address this concern, adjuvant pharmacotherapy concomitant to or after EVAR could provide an ideal solution. Several studies have suggested a potential association between aneurysm sac regression and treatment with drugs like statins \[[@r80], [@r81]\], doxycycline \[[@r82]\], calcium channel blockers \[[@r83]\], and tranexamic acid \[[@r84]\]. However, the use of pharmacotherapy remains controversial because of inconsistent results \[[@r85]\]. Further studies are needed to clarify the role of adjuvant pharmacotherapy in enhancing sac regression and in reducing the risk of endoleaks after EVAR. The combination of local drug delivery plus EVAR has promise in terms of utilizing pharmacotherapy as an adjuvant treatment. Indeed, we \[[@r86]\] and others \[[@r87]\] have filed patent applications for devices that comprise a stent graft and a drug delivery system. Progress in this area could drive the development of less invasive therapeutic strategies for AAA treatment.

CONCLUSION
==========

Research conducted over the last 25 years has substantially deepened our understanding of the pathophysiology underlying AAA. However, this understanding has not translated into the development of pharmacologic therapies that improve the outcomes of AAA patients. Going forward, strategic approaches must be developed to continue to make progress in AAA research in order to offer effective pharmacotherapy to patients in addition to open repair and EVAR.
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###### 

Pharmacologic therapy that prevents AAA progression in animal models.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Authors**                      **Year**        **Animal Model**                **AAA Inducer**          **Intervention**\                       **Target**                **Effect on Progression of Preexisting AAA**
                                                                                                            **(Period)**                                                      
  -------------------------------- --------------- ------------------------------- ------------------------ --------------------------------------- ------------------------- ----------------------------------------------
  Huffman\                         2000            Rats                            Elastase                 Doxycycline\                            MMP                       Stopped progression\
  *et al.* \[[@r26]\]                                                                                       (daily on days 7--21)                                             (on day 21)

  Yoshimura *et al.* \[[@r22]\]    2005            Mice                            CaCl~2~                  SP600125\                               JNK                       Stopped progression\
                                                                                                            (daily on days 43--84)                                            (on day 84)

  Apoe-/- mice                     Ang II\         SP600125\                       Stopped progression\                                                                       
                                   (for 28 days)   (daily on days 29--84)          (on day 84)                                                                                

  Isenburg\                        2007            Rats                            CaCl~2~                  PGG\                                    Elastolytic degradation   Decreased progression\
  *et al.* \[[@r28]\]                                                                                       (local injection on days 28)                                      (on day 56)

  Inoue *et al.* \[[@r16]\]        2009            Apoe-/- mice                    Ang II\                  Candesartan\                            Ang II receptor           Decreased progression\
                                                                                   (for 28 days)            (daily on days 28--168)                                           (on day 168)

  Lisinopril\                      ACE             Decreased progression\                                                                                                     
  (daily on days 28--168)                          (on day 168)                                                                                                               

  Dai *et al.* \[[@r20]\]          2011            Rats                            Xenograft                Cyclosporine A\                         Immune response           Decreased progression\
                                                                                                            (daily on days 14--21)                                            (on day 70)

  Ghoshal\                         2012            Apoe-/- mice                    Ang II\                  Celecoxib\                              COX-2                     Stopped progression\
  *et al.* \[[@r18]\]                                                              (for 56 days)            (daily on days 21--56)                                            (on day 56)

  Morimoto\                        2012            Rats                            Elastase and CaCl~2~     Edaravone\                              ROS                       Stopped progression\
  *et al.* \[[@r31]\]                                                                                       (daily on days 7--28)                                             (on day 28)

  Mukherjee *et al.* \[[@r19]\]    2012            Mice                            Ang II\                  Celecoxib\                              COX-2                     Decreased progression\
                                                                                   (for 28 days)            (daily on days 5--28)                                             (on day 28)

  Johnston\                        2013            Mice                            Elastase                 Anakinra\                               IL-1β                     Decreased progression\
  *et al.* \[[@r13]\]                                                                                       (continuously on days 7--21)                                      (on day 21)

  Iida *et al.* \[[@r14]\]         2013            Mice                            Elastase                 MKEY peptide\                           CXCL4--CCL5               Stopped progression\
                                                                                                            (daily on days 5--14)                                             (on day 14)

  Rouer *et al.* \[[@r21]\]        2014            Mice                            Elastase                 Rapamycin\                              Immune response           Decreased progression\
                                                                                                            (daily on days 4--10)                                             (on day 10)

  Seto *et al.* \[[@r17]\]         2014            Apoe-/- mice                    Ang II\                  Aliskiren\                              Renin                     Decreased progression\
                                                                                   (for 28 days)            (daily on days 29--56)                                            (on day 56)

  Michineau *et al.* \[[@r15]\]    2014            Mice                            CaCl~2~                  AMD3100\                                SDF-1/CXCR4               Decreased progression\
                                                                                                            (continuously on days 4--14)                                      (on day 14)

  Rats                             Xenograft       AMD3100\                        Decreased progression\                                                                     
                                                   (continuously on days 14--42)   (on day 42)                                                                                

  Cheng *et al.* \[[@r23]\]        2014            Apoe-/- mice                    Ang II\                  DAPT\                                   Notch                     Decreased progression\
                                                                                   (for 28 days)            (3 times a week on days 8--28)                                    (on day 28)

  Yan *et al.* \[[@r24]\]          2015            Mice                            CaCl~2~                  TLR2-neutralizing antibody\             TLR2                      Decreased progression\
                                                                                                            (weekly on days 42--84)                                           (on day 84)

  Nosoudi\                         2015            Rats                            CaCl~2~                  Nanoparticles loaded with batimastat\   MMP                       Stopped progression\
  *et al.* \[[@r27]\]                                                                                       (weekly on days 10--38)                                           (on day 38)

  Ren *et al.* \[[@r32]\]          2016            Mice                            Elastase                 Andrographolide\                        Inflammation              Decreased progression\
                                                                                                            (daily on days 7--14)                                             (on day 14)

  Moran *et al.* \[[@r33]\]        2016            Apoe-/- mice                    Ang II\                  B9330\                                  B2R                       Stopped progression\
                                                                                   (for 28 days)            (every other day on days 29--56)                                  (on day 56)

  Rats                             CaPO~4~         B9330\                          Decreased progression\                                                                     
                                                   (single injection on days 7)    (on day 28)                                                                                

  **Authors**                      **Year**        **Animal Model**                **AAA Inducer**          **Intervention**\                       **Target**                **Effect on Progression of Preexisting AAA**
                                                                                                            **(Period)**                                                      

  Nosoudi\                         2016            Rats                            CaCl~2~                  PGG-loaded nanoparticles\               Elastolytic degradation   Decreased progression\
  *et al.* \[[@r29]\]                                                                                       (every other week on days 10--38)                                 (on day 38)

  Pope *et al.* \[[@r34]\]         2016            Mice                            Elastase                 Resolvin D2\                            Inflammation              Decreased progression\
                                                                                                            (every third day on days 3--14)                                   (on day 14)

  Harada\                          2017            Mice                            CaCl~2~                  PF573228\                               FAK                       Stopped progression\
  *et al.* \[[@r25]\]                                                                                       (daily on days 22--42)                                            (on day 42)

  Di Gregoli *et al.* \[[@r35]\]   2017            Apoe-/- or Ldlr-/- mice         Ang II\                  miR-181b LNA inhibitor\                 TIMP-3                    Decreased progression\
                                                                                   (for 28 days)            (weekly on days 29--42)                                           (on day 42)

  Wang *et al.* \[[@r30]\]         2017            Mice                            Elastase                 Necrostatin-1s\                         Necroptosis               Stopped progression\
                                                                                                            (daily on days 7--14)                                             (on day 14)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AAA = abdominal aortic aneurysm; ACE = angiotensin converting enzyme; Ang II = angiotensin II; Apoe-/- = apolipoprotein E deficient; B2R = kinin B2 receptor; COX-2 = cyclooxygenase-2; FAK = focal adhesion kinase; 1L-1β = interleukin-1β; JNK = c-Jun N-terminal kinase; Ldlr-/- = low density lipoprotein receptor deficient; LNA = locked nucleic acid; MMP = matrix metalloproteinase; mTOR = mammalian target of rapamycin; PGG = pentagalloyl glucose; ROS = reactive oxygen species; SDF-1 = stromal cell-derived factor 1; TIMP-3 = tissue inhibitor of metalloproteinase-3; TLR2 = toll-like receptor2.

###### 

Pharmacologic therapy that reduces levels of AAA-related markers in human AAA explants.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Authors**                    **Year**                 **Intervention**                                                                            **Target**                **Effect on Human AAA in *Ex Vivo* Culture**
  ------------------------------ ------------------------ ------------------------------------------------------------------------------------------- ------------------------- -------------------------------------------------------------------------------------------
  Franklin *et al.* \[[@r36]\]   1999                     Tetracycline                                                                                MMP                       Reduced secretion of MMP-9 and MCP-1

  Franklin *et al.* \[[@r41]\]   1999                     Indomethacin                                                                                COX-2                     Reduced secretion of PGE2, IL-1β, and IL-6

  Walton *et al.* \[[@r42]\]     1999                     Indomethacin                                                                                COX-2                     Reduced secretion of PGE2, IL-1β, and IL-6

  Mefenamic acid                 COX-2                    Reduced secretion of PGE2, IL-1β, and IL-6                                                                            

  Nagashima\                     2002                     Cerivastatin                                                                                Mevalonate pathway        Reduced secretion of MMP-9
  *et al.* \[[@r47]\]                                                                                                                                                           

  Bayston *et al.* \[[@r43]\]    2003                     Indomethacin                                                                                COX-2                     Reduced secretion of IL-6

  Dexamethasone                  COX-2                    Reduced secretion of IL-6                                                                                             

  Nagashima\                     2004                     Trapidil                                                                                    CD40-CD40L interaction    Reduced production of MMP-2
  *et al.* \[[@r48]\]                                                                                                                                                           

  Anti-CD154 antibody            CD40-CD40L interaction   Reduced production of MMP-2                                                                                           

  Moran *et al.* \[[@r39]\]      2005                     Irbesartan                                                                                  Angiotensin II receptor   Reduced secretion of OPG

  Dai *et al.* \[[@r38]\]        2005                     Recombinant human active TGF-β1                                                             TGF-β1                    Reduced secretion of MMP-9 and MMP-2

  Yoshimura\                     2005                     SP600125                                                                                    JNK                       Reduced secretion of MMP-9 under basal and TNF-α-stimulated conditions
  *et al.* \[[@r22]\]                                                                                                                                                           

  Moran *et al.* \[[@r49]\]      2009                     Rosiglitazone\                                                                              PPARγ                     Reduced secretion and production of OPG, production of MMP-9, and secretion of IL-6
                                                          (PPARγ agonist)                                                                                                       

  Pioglitazone\                  PPARγ                    Reduced secretion and production of OPG, production of MMP-9 and secretion of IL-6                                    
  (PPARγ agonist)                                                                                                                                                               

  Shintani *et al.* \[[@r40]\]   2011                     Recombinant human HGF                                                                                                 Reduced secretion of MCP-1 under TNF-α-stimulated conditions

  Imidaprilat                    ACE                      Reduced secretion of MCP-1 under TNF-α-stimulated conditions                                                          

  Perindoprilat                  ACE                      Reduced secretion of MCP-1 under TNF-α-stimulated conditions                                                          

  **Authors**                    **Year**                 **Intervention**                                                                            **Target**                **Effect on Human AAA in *Ex Vivo* Culture**

  Yokoyama\                      2012                     ONO-AE3-208\                                                                                EP4                       Reduced secretion of MMP-2 and production of IL-6
  *et al.* \[[@r44]\]                                     (EP4 antagonist)                                                                                                      

  Vucevic *et al.* \[[@r50]\]    2012                     Recombinant human IL-10                                                                     Immune response           Reduced secretion of IL-6 under PMA-stimulated conditions

  Yamashita\                     2013                     PF573228                                                                                    FAK                       Reduced activation levels of ERK and JNK, and reduced secretion of MCP-1 and MMP-9
  *et al.* \[[@r45]\]                                                                                                                                                           

  Yoshimura\                     2015                     Simvastatin                                                                                 Mevalonate pathway        Reduced activation levels of JNK and NF-κB under TNF-α-stimulated conditions\
  *et al.* \[[@r46]\]                                                                                                                                                           Reduced secretion of MMP-9, MCP-2, and CXCL-5 under basal and TNF-α-stimulated conditions

  Pitavastatin                   Mevalonate pathway       Reduced secretion of MMP-9, MCP-2, and CXCL-5 under basal and TNF-α-stimulated conditions                             

  NSC23766                       Rac1                     Reduced secretion of MMP-9, MCP-2, and CXCL-5 under basal and TNF-α-stimulated conditions                             

  Moran *et al.* \[[@r33]\]      2016                     B9330                                                                                       B2R                       Reduced secretion of MMP-9, OPG, and osteopontin

  Harada *et al.* \[[@r25]\]     2017                     PF573228                                                                                    FAK                       Reduced secretion of MCP-1 and MMP-9 under TNF-α-stimulated conditions
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AAA = abdominal aortic aneurysm; ACE = angiotensin converting enzyme; B2R = kinin B2 receptor; COX-2 = cyclooxygenase-2; EP4 = prostanoid receptor EP4; ERK = extracellular signal-regulated kinase; FAK = focal adhesion kinase; HGF = hepatocyte growth factor; 1L-1β = interleukin-1β; IL-6 = interleukin-6; IL-10 = interleukin-10; JNK = c-Jun N-terminal kinase; MCP = monocyte chemotactic protein; MMP = matrix metalloproteinase; NF-κB = nuclear factor-κB; OPG = osteoprotegerin; PGE2 = prostaglandin E2; PMA = phorbol myristate acetate; PPARγ = peroxisome proliferator-activated receptor-γ; TGF-β1 = transforming growth factor-β1; TNF-α = tumor necrosis factor-α.

###### 

Completed randomized clinical trials of pharmacologic therapy to prevent AAA progression.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Authors**                    **Year**   **Intervention**   **Sample Size**   **Follow-up, Months**   **Growth Rate, mm/year**                **p-value**   
  ------------------------------ ---------- ------------------ ----------------- ----------------------- --------------------------------------- ------------- -------
  Mosorin *et al.* \[[@r54]\]    2001       Doxycycline\       32                18                      1.5                                     3.0           NS
                                            (3 months)                                                                                                         

  Vammen *et al.* \[[@r55]\]     2001       Roxithromycin\     92                18                      1.56                                    2.75          0.02
                                            (28 days)                                                                                                          

  PATI \[[@r61]\]                2002       Propranolol        548               30                      2.2\                                    2.6           NS
                                                                                                         (High dropout rate and low QOL score)                 

  Hogh *et al.* \[[@r56]\]       2009       Roxithromycin\     84                60                      1.61                                    2.52          0.055
                                            (28 days)                                                                                                          

  Karlsson *et al.* \[[@r57]\]   2009       Azithromycin\      247               18                      2.2                                     2.2           NS
                                            (15 weeks)                                                                                                         

  Meijer *et al.* \[[@r58]\]     2013       Doxycycline        286               18                      4.1 (higher than placebo)               3.3           0.016

  Sillesen *et al.* \[[@r62]\]   2015       Pemirolast         326               12                      2.58 (10 mg)\                           2.04          NS
                                                                                                         2.34 (25 mg)\                                         
                                                                                                         2.71 (40 mg)                                          

  Bicknell *et al.* \[[@r63]\]   2016       Perindopril\       227               24                      1.77 (perindopril)\                     1.68          NS\
                                            Amlodipine                                                   1.81 (amlodipine)                                     NS
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------

AAA = abdominal aortic aneurysm; NS = not significant; PATI = propranolol aneurysm trial investigators; QOL = quality of life.

###### 

Ongoing randomized clinical trials of pharmacologic therapy to prevent AAA progression.

  ------------------------------------------------------------------------------------------------------------------------------------------
  **NCT Number**   **Intervention**   **Phase**   **Primary Outcome**   **Status**                   **Estimated**\        **Sample Size**
                                                                                                     **Completion Date**   
  ---------------- ------------------ ----------- --------------------- ---------------------------- --------------------- -----------------
  NCT01756833      Doxycycline        2           Growth by CT\         Ongoing but not recruiting   September 2019        261
                                                  at 48 months                                                             

  NCT02070653      Ticagrelor         2           Growth by MRI\        Ongoing but not Recruiting   July 2017             145
                                                  at 24 months                                                             

  NCT01683084      Telmisartan        4           Growth by CT\         Ongoing but not recruiting   August 2017           300
                                                  at 48 months                                                             

  NCT01904981      Valsartan *vs*.\   4           Growth by CT\         Unknown                      October 2016          400
                   Atenolol                       at 12 months                                                             

  NCT02225756      Cyclosporine A     2           Growth by CT\         Recruiting                   September 2018        360
                                                  at 12 months                                                             

  NCT02345590      Eplerenone         4           Growth by MRI\        Recruiting                   December 2019         172
                                                  at 12 months                                                             
  ------------------------------------------------------------------------------------------------------------------------------------------

AAA = abdominal aortic aneurysm; CT = computed tomography; MRI = magnetic resonance imaging; NCT = National Clinical Trial.

###### 

Medical management recommendations for preventing AAA progression in current practice guidelines.

  **Guidelines**                                                                                                                               **Year**                                                                  **Recommendation**                                                                          **Class of Recommendation**                                                                                   **Level of Evidence**
  -------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------
  ESC \[[@r73]\]                                                                                                                               2014                                                                      Encourage smoking cessation to slow the growth of the AAA.                                  I (Evidence and/or general agreement that a given treatment or procedure in beneficial, useful, effective.)   B (Data derived from a single randomized clinical trial or large non-randomized studies.)
  Consider the use of statins and ACE inhibitors to reduce aortic complications in patients with small AAAs.                                   IIb (Usefulness/efficacy is less well established by evidence/opinion.)   B (Data derived from a single randomized clinical trial or large non-randomized studies.)                                                                                                                 
  SVS \[[@r72]\]                                                                                                                               2009                                                                      Encourage smoking cessation to reduce the risk of AAA growth and rupture.                   Strong                                                                                                        High
  Consider the use of statins to reduce the risk of AAA growth.                                                                                Weak                                                                      Low                                                                                                                                                                                                       
  Uncertain benefits for the use of doxycycline, roxithromycin, ACE inhibitors, and ARBs for reducing the risk of AAA expansion and rupture.   Weak                                                                      Low                                                                                                                                                                                                       
  Do not use β-blockers to reduce the risk of AAA expansion and rupture.                                                                       Strong                                                                    Moderate                                                                                                                                                                                                  

AAA = abdominal aortic aneurysm; ACE = angiotensin converting enzyme; ARB = angiotensin receptor blocker; ESC = European Society of Cardiology; SVS = Society for Vascular Surgery.

###### 

Possible future roles of pharmacologic treatments in the management of AAA.

  **Level of Prevention**   **Target Population**      **Treatment Goal**                                                 **Possible Treatment Strategies**
  ------------------------- -------------------------- ------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------
  Primary prevention        At-risk patients           Reduce the incidence of AAA.                                       Use pharmacologic treatment of risk factors for AAA, such as hypertension and hypercholesterolemia.
  Secondary prevention      Patients with small AAAs   Reduce the progression of AAA and the risk of surgical referral.   Use pharmacologic therapy to stop or slow the progression of AAA.
  Tertiary prevention       Patients with large AAAs   Reduce AAA-related complications and mortality.                    Use adjuvant pharmacologic treatment to reduce peri- and postoperative complications and to improve EVAR results.

AAA = abdominal aortic aneurysm; EVAR = endovascular aneurysm repair.

###### 

Challenges to using pharmacotherapy to prevent AAA progression.

  **Current Concerns**                                                        **Possible Strategies to Address These Concerns**
  --------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------
  Appropriate drug targets may not have been identified.                      Consider the appropriate use of animal models and human tissue samples to gain a better understanding of human AAA pathophysiology and pathogenesis.
  Few pharmacokinetic approaches have been used.                              Develop AAA-targeted DDSs to more effectively concentrate drugs at the site of the AAA.
  Pharmacotherapy may not take the heterogeneity of human AAA into account.   Use appropriate biomarkers to develop personalized medicine for patients with AAA.

AAA = abdominal aortic aneurysm; DDS = drug delivery system.
